Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2023-08, Vol.164, p.114934-114934, Article 114934
Hauptverfasser: Gioé-Gallo, Claudia, Ortigueira, Sandra, Brea, José, Raïch, Iu, Azuaje, Jhonny, Paleo, M. Rita, Majellaro, Maria, Loza, María Isabel, Salas, Cristian O., García-Mera, Xerardo, Navarro, Gemma, Sotelo, Eddy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 114934
container_issue
container_start_page 114934
container_title Biomedicine & pharmacotherapy
container_volume 164
creator Gioé-Gallo, Claudia
Ortigueira, Sandra
Brea, José
Raïch, Iu
Azuaje, Jhonny
Paleo, M. Rita
Majellaro, Maria
Loza, María Isabel
Salas, Cristian O.
García-Mera, Xerardo
Navarro, Gemma
Sotelo, Eddy
description Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs. [Display omitted] •Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs.
doi_str_mv 10.1016/j.biopha.2023.114934
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2820027126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332223007242</els_id><sourcerecordid>2820027126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS1ERbeFb4CQj1yy-E_WiS9IqCpQqRI9lLM1mUyyXiX2YmeRylfol8ZVWo6cLI1_b57mPcbeS7GVQppPh23n43EPWyWU3kpZW12_Yhtpd6IyQjSv2UY0O11prdQ5u8j5IITYGd2-Yee6UdoI1WzY490e0gwYpzh6hIn7kP24XzKnmdLow8iHFGe-7IljQQEXSv4PLD4GHgcOfII0lr84TYQv0_wQimDxyBFCgM6H6HueCOm4xMRhjMHn4tFTMQuUeJ9OY37LzgaYMr17fi_Zz6_X91ffq9sf326uvtxWWIt2qVRnEW0nrbVEtgcD1pAw7aCwq0EbiRZr25CyoBCkbhspG9mIRnVkB4P6kn1c9x5T_HWivLjZZ6RpgkDxlJ1qlSjhSGUKWq8opphzosEdk58hPTgp3FMN7uDWGtxTDW6tocg-PDucupn6f6KX3AvweQWo3PnbU3IZPQWk3peUFtdH_3-HvyFdnj8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2820027126</pqid></control><display><type>article</type><title>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gioé-Gallo, Claudia ; Ortigueira, Sandra ; Brea, José ; Raïch, Iu ; Azuaje, Jhonny ; Paleo, M. Rita ; Majellaro, Maria ; Loza, María Isabel ; Salas, Cristian O. ; García-Mera, Xerardo ; Navarro, Gemma ; Sotelo, Eddy</creator><creatorcontrib>Gioé-Gallo, Claudia ; Ortigueira, Sandra ; Brea, José ; Raïch, Iu ; Azuaje, Jhonny ; Paleo, M. Rita ; Majellaro, Maria ; Loza, María Isabel ; Salas, Cristian O. ; García-Mera, Xerardo ; Navarro, Gemma ; Sotelo, Eddy</creatorcontrib><description>Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs. [Display omitted] •Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2023.114934</identifier><identifier>PMID: 37236027</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Abuse drugs ; Animals ; Cannabinoid Receptor Agonists - pharmacology ; Cannabinoids ; Cannabis ; CB1 ; CB2 ; Designer drugs ; Designer Drugs - toxicity ; Indazole ; Indole ; Ligands ; Mice ; SCRAs ; Structure-Activity Relationship ; Synthetic cannabinoid receptor agonists ; Synthetic cannabinoids NPS</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2023-08, Vol.164, p.114934-114934, Article 114934</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</citedby><cites>FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</cites><orcidid>0000-0001-5218-6351 ; 0000-0001-9726-0455 ; 0000-0001-5571-2812 ; 0000-0002-5523-1979 ; 0000-0003-3490-7703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2023.114934$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37236027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gioé-Gallo, Claudia</creatorcontrib><creatorcontrib>Ortigueira, Sandra</creatorcontrib><creatorcontrib>Brea, José</creatorcontrib><creatorcontrib>Raïch, Iu</creatorcontrib><creatorcontrib>Azuaje, Jhonny</creatorcontrib><creatorcontrib>Paleo, M. Rita</creatorcontrib><creatorcontrib>Majellaro, Maria</creatorcontrib><creatorcontrib>Loza, María Isabel</creatorcontrib><creatorcontrib>Salas, Cristian O.</creatorcontrib><creatorcontrib>García-Mera, Xerardo</creatorcontrib><creatorcontrib>Navarro, Gemma</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><title>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs. [Display omitted] •Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs.</description><subject>Abuse drugs</subject><subject>Animals</subject><subject>Cannabinoid Receptor Agonists - pharmacology</subject><subject>Cannabinoids</subject><subject>Cannabis</subject><subject>CB1</subject><subject>CB2</subject><subject>Designer drugs</subject><subject>Designer Drugs - toxicity</subject><subject>Indazole</subject><subject>Indole</subject><subject>Ligands</subject><subject>Mice</subject><subject>SCRAs</subject><subject>Structure-Activity Relationship</subject><subject>Synthetic cannabinoid receptor agonists</subject><subject>Synthetic cannabinoids NPS</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS1ERbeFb4CQj1yy-E_WiS9IqCpQqRI9lLM1mUyyXiX2YmeRylfol8ZVWo6cLI1_b57mPcbeS7GVQppPh23n43EPWyWU3kpZW12_Yhtpd6IyQjSv2UY0O11prdQ5u8j5IITYGd2-Yee6UdoI1WzY490e0gwYpzh6hIn7kP24XzKnmdLow8iHFGe-7IljQQEXSv4PLD4GHgcOfII0lr84TYQv0_wQimDxyBFCgM6H6HueCOm4xMRhjMHn4tFTMQuUeJ9OY37LzgaYMr17fi_Zz6_X91ffq9sf326uvtxWWIt2qVRnEW0nrbVEtgcD1pAw7aCwq0EbiRZr25CyoBCkbhspG9mIRnVkB4P6kn1c9x5T_HWivLjZZ6RpgkDxlJ1qlSjhSGUKWq8opphzosEdk58hPTgp3FMN7uDWGtxTDW6tocg-PDucupn6f6KX3AvweQWo3PnbU3IZPQWk3peUFtdH_3-HvyFdnj8</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Gioé-Gallo, Claudia</creator><creator>Ortigueira, Sandra</creator><creator>Brea, José</creator><creator>Raïch, Iu</creator><creator>Azuaje, Jhonny</creator><creator>Paleo, M. Rita</creator><creator>Majellaro, Maria</creator><creator>Loza, María Isabel</creator><creator>Salas, Cristian O.</creator><creator>García-Mera, Xerardo</creator><creator>Navarro, Gemma</creator><creator>Sotelo, Eddy</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5218-6351</orcidid><orcidid>https://orcid.org/0000-0001-9726-0455</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-3490-7703</orcidid></search><sort><creationdate>202308</creationdate><title>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</title><author>Gioé-Gallo, Claudia ; Ortigueira, Sandra ; Brea, José ; Raïch, Iu ; Azuaje, Jhonny ; Paleo, M. Rita ; Majellaro, Maria ; Loza, María Isabel ; Salas, Cristian O. ; García-Mera, Xerardo ; Navarro, Gemma ; Sotelo, Eddy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abuse drugs</topic><topic>Animals</topic><topic>Cannabinoid Receptor Agonists - pharmacology</topic><topic>Cannabinoids</topic><topic>Cannabis</topic><topic>CB1</topic><topic>CB2</topic><topic>Designer drugs</topic><topic>Designer Drugs - toxicity</topic><topic>Indazole</topic><topic>Indole</topic><topic>Ligands</topic><topic>Mice</topic><topic>SCRAs</topic><topic>Structure-Activity Relationship</topic><topic>Synthetic cannabinoid receptor agonists</topic><topic>Synthetic cannabinoids NPS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gioé-Gallo, Claudia</creatorcontrib><creatorcontrib>Ortigueira, Sandra</creatorcontrib><creatorcontrib>Brea, José</creatorcontrib><creatorcontrib>Raïch, Iu</creatorcontrib><creatorcontrib>Azuaje, Jhonny</creatorcontrib><creatorcontrib>Paleo, M. Rita</creatorcontrib><creatorcontrib>Majellaro, Maria</creatorcontrib><creatorcontrib>Loza, María Isabel</creatorcontrib><creatorcontrib>Salas, Cristian O.</creatorcontrib><creatorcontrib>García-Mera, Xerardo</creatorcontrib><creatorcontrib>Navarro, Gemma</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gioé-Gallo, Claudia</au><au>Ortigueira, Sandra</au><au>Brea, José</au><au>Raïch, Iu</au><au>Azuaje, Jhonny</au><au>Paleo, M. Rita</au><au>Majellaro, Maria</au><au>Loza, María Isabel</au><au>Salas, Cristian O.</au><au>García-Mera, Xerardo</au><au>Navarro, Gemma</au><au>Sotelo, Eddy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2023-08</date><risdate>2023</risdate><volume>164</volume><spage>114934</spage><epage>114934</epage><pages>114934-114934</pages><artnum>114934</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs. [Display omitted] •Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>37236027</pmid><doi>10.1016/j.biopha.2023.114934</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5218-6351</orcidid><orcidid>https://orcid.org/0000-0001-9726-0455</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-3490-7703</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2023-08, Vol.164, p.114934-114934, Article 114934
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2820027126
source MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Abuse drugs
Animals
Cannabinoid Receptor Agonists - pharmacology
Cannabinoids
Cannabis
CB1
CB2
Designer drugs
Designer Drugs - toxicity
Indazole
Indole
Ligands
Mice
SCRAs
Structure-Activity Relationship
Synthetic cannabinoid receptor agonists
Synthetic cannabinoids NPS
title Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T23%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20insights%20emerging%20from%20the%20characterization%20of%20a%20large%20collection%20of%20synthetic%20cannabinoid%20receptor%20agonists%20designer%20drugs&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Gio%C3%A9-Gallo,%20Claudia&rft.date=2023-08&rft.volume=164&rft.spage=114934&rft.epage=114934&rft.pages=114934-114934&rft.artnum=114934&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2023.114934&rft_dat=%3Cproquest_cross%3E2820027126%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2820027126&rft_id=info:pmid/37236027&rft_els_id=S0753332223007242&rfr_iscdi=true